PRESS RELEASE
News
-
-
-
-
PRESS RELEASE
Spexis announces extension of moratorium, receipt of an additional payment related to the sale of a preclinical antibiotics program and reversion of the lonodelestat license from Santhera
Spexis AG extends moratorium and receives payment for antibiotics program sale while reverting lonodelestat license from Santhera -
PRESS RELEASE
Spexis announces closing of sale of preclinical antibiotics program to Basilea
Spexis AG announces the closing of the sale of a preclinical antibiotics program to Basilea, which will pay up to CHF 2 million for the program. The program targets Gram-negative bacteria, including multidrug-resistant strains. The sale is part of Spexis' strategy to divest non-core programs and assets to focus on rare diseases and oncology -
-
PRESS RELEASE
Spexis Announces Changes to the Executive Committee
-
-
-
